Show simple item record

dc.contributor.authorFrancesca Chiodi*
dc.contributor.authorGabriella Scarlatti*
dc.date.accessioned2021-02-11T15:28:07Z
dc.date.available2021-02-11T15:28:07Z
dc.date.issued2018*
dc.date.submitted2018-11-16 17:17:57*
dc.identifier29690*
dc.identifier.issn16648714*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/49485
dc.description.abstractMultiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarged during HIV-1 infection. Antibodies with the capacity to neutralize a broad range of HIV-1 isolates can be detected only in a minority of infected patients, after a year or more from acute infection. An open question is whether the inability of producing neutralizing HIV-1 antibodies is somehow linked to the B cell immunopathology observed in patients. In this research topic we invited scientists to summarize the current state of knowledge on regulation and development of B cells and antibody responses during HIV-1 infection; fifteen contributions were received comprising both reviews and original articles. The articles are related to B cell dysfunctions identified in HIV-1 infected individuals, production of different types of antibodies (neutralizing versus non neutralizing, and of different isotypes) in vivo during HIV-1 infection and the biological factors which may impact on this process, clinical potential and applications of anti-HIV antibodies and how to achieve neutralizing antibody responses to HIV-1 epitopes upon vaccination. The topic has gathered articles on front-line research undertaken in the field of B cells and antibodies in HIV-1 infection. It is our hope that the collection of articles presented in this book may be useful for new and experienced scholars in the field and add a piece to the complex puzzle of knowledge needed for the development of an HIV-1 vaccine.*
dc.languageEnglish*
dc.relation.ispartofseriesFrontiers Research Topics*
dc.subjectR5-920*
dc.subjectRC581-607*
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.otherauto-antibodies to CCR5*
dc.subject.otherBAFF*
dc.subject.otherGene Expression*
dc.subject.otherclinical potential of HIV-1 antibodies*
dc.subject.othermucosal IgA responses*
dc.subject.otherFcRL4*
dc.subject.otherneutralizing and non neutralizing HIV-1 antibodies*
dc.subject.otherHIV-1 vaccine targets*
dc.subject.otherB cells*
dc.subject.otherCXCL13*
dc.subject.othermaternal HIV antibodies*
dc.titleHIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies*
dc.typebook
oapen.identifier.doi10.3389/978-2-88945-461-7*
oapen.relation.isPublishedBybf5ce210-e72e-4860-ba9b-c305640ff3ae*
oapen.relation.isbn9782889454617*
oapen.pages171*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/